163 related articles for article (PubMed ID: 29609548)
41. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Naidoo N; Meiring S; Quan V; Nokeri V; Fortuin-de Smit M; Malope-Kgokong B; Moore D; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Kularatne R; Conklin L; O'Brien KL; Zell ER; Klugman K; Whitney CG; von Gottberg A;
Clin Infect Dis; 2014 Sep; 59(6):808-18. PubMed ID: 24917657
[TBL] [Abstract][Full Text] [Related]
44. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
Lewnard JA; Givon-Lavi N; Dagan R
Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
[TBL] [Abstract][Full Text] [Related]
45. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
[TBL] [Abstract][Full Text] [Related]
46. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
47. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies.
Bar-Zeev N; Swarthout TD; Everett DB; Alaerts M; Msefula J; Brown C; Bilima S; Mallewa J; King C; von Gottberg A; Verani JR; Whitney CG; Mwansambo C; Gordon SB; Cunliffe NA; French N; Heyderman RS;
Lancet Glob Health; 2021 Jul; 9(7):e989-e998. PubMed ID: 34143997
[TBL] [Abstract][Full Text] [Related]
48. Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings.
von Mollendorf C; Lim R; Choummanivong M; Sychareun V; Vilivong K; Lai JYR; Chan J; Dunne EM; Phommachanh S; Moore KA; Ortika BD; Gray A; Weaver R; Mayxay M; Phetsouvanh R; Datta SS; Fox K; Newton PN; Mulholland KE; Nguyen CD; Dance DAB; Satzke C; Russell FM
Expert Rev Vaccines; 2022 Aug; 21(8):1137-1145. PubMed ID: 34378467
[TBL] [Abstract][Full Text] [Related]
49. Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccines.
Picazo J; Dueñas J; Ramirez A; Perez AR; Padilla E; Herrero S; Gallegos C; Culebras E; Balseiro C; Mendez C
BMC Infect Dis; 2013 Oct; 13():503. PubMed ID: 24498901
[TBL] [Abstract][Full Text] [Related]
50. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
51. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
[TBL] [Abstract][Full Text] [Related]
52. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
Gidding HF; Sheridan S; Fathima P; Moore HC; Liu B; McIntyre PB; Palmu AA;
Pediatr Infect Dis J; 2019 Aug; 38(8):860-865. PubMed ID: 30985507
[TBL] [Abstract][Full Text] [Related]
53. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.
Singleton R; Wenger J; Klejka JA; Bulkow LR; Thompson A; Sarkozy D; Emini EA; Gruber WC; Scott DA
Pediatr Infect Dis J; 2013 Mar; 32(3):257-63. PubMed ID: 23001026
[TBL] [Abstract][Full Text] [Related]
54. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD
Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622
[TBL] [Abstract][Full Text] [Related]
55. The Effect of 13-Valent Pneumococcal Conjugate Vaccine on the Serotype Distribution and Antibiotic Resistance Profiles in Children With Invasive Pneumococcal Disease.
Gaviria-Agudelo CL; Jordan-Villegas A; Garcia C; McCracken GH
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):253-259. PubMed ID: 26907814
[TBL] [Abstract][Full Text] [Related]
56. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
[TBL] [Abstract][Full Text] [Related]
57. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
[TBL] [Abstract][Full Text] [Related]
58. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
59. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
[TBL] [Abstract][Full Text] [Related]
60. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
